COVID-19 jab from Pfizer/ BioNTech to become the first to win emergency nod in U.S.

 

• BNT162b2, the experimental COVID-19 vaccine from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) alliance, is likely to become the first to receive the emergency nod in the U.S., Bloomberg reports.
• Study sponsors “provided adequate information to ensure the vaccine’s quality and consistency for authorization of the product under a EUA”, agency reviewers have said ahead of a panel review set for Thursday.
• The vaccine has already won emergency approval in the U.K., and according to Wall Street analysts, the approval is possible within days.
• The rival candidate from Moderna, Inc. (NASDAQ:MRNA) using a similar messenger-RNA technology is set to face its review for the emergency use authorization next week.
• https://seekingalpha.com/news/3642461-covidminus-19-jab-from-pfizer-biontech-to-become-first-to-win-emergency-nod-in-u-s